ATXA THERAPEUTICS LIMITED

ATXA Therapeutics is a clinical‑stage pharmaceutical company dedicated to delivering life‑changing treatments for cardiopulmonary disease. By targeting the thromboxane receptor (TP)—a pivotal driver of pathology in the heart and lungs—the company is pioneering a new class of antagonists that aim to halt disease progression and improve patient outcomes.

The firm’s flagship programme centres on NTP42, a novel TP antagonist that has successfully completed a Phase 1 safety and tolerability study in healthy volunteers. Building on this momentum, ATXA is advancing its pipeline towards later‑stage trials, with a clear focus on translating cutting‑edge science into therapies that address unmet medical needs. The company’s innovative approach has already earned recognition, with its Founder and CEO receiving the 2024 NovaUCD Innovation Award.

ATXA Therapeutics serves the global medical community, collaborating with research institutions, regulatory bodies and healthcare partners to bring its cardiopulmonary solutions from the laboratory to the bedside.